Ebola

Experimental Antibody Tightens Up Leaky Blood Vessels

Treatment Could Benefit Patients With a Variety of Illnesses

blood vessels

Our blood is a miraculous mix of cells and critical fluids that keep our organs running and fight off dangerous infections. Of course, for blood to do its job, it has to stay in our veins and arteries, which is easier said than done for people with certain illnesses. Fortunately, a recent IRP study has demonstrated the promise of a potential new treatment for people with dangerously leaky blood vessels.

Several life-threatening conditions, including Ebola and sepsis due to an uncontrolled infection, cause the fluid component of blood to leak out of blood vessels. IRP senior investigator Kirk Druey, M.D., however, came to study the phenomenon through a very rare ailment called Clarkson disease, which causes patients to periodically experience ‘flares’ or ‘episodes’ when their veins and arteries suddenly and inexplicably start leaking.

Leading the Charge Against Infectious Disease

Government Awards Recognize H. Clifford Lane’s Four Decades of Research Achievements

Dr. H. Clifford Lane

The remarkable career of H. Clifford Lane, M.D., might have gone very differently if a NIH scientist hadn’t accidentally eavesdropped on Dr. Lane’s conversation with a colleague in 1979. After hearing Dr. Lane mention that he had missed the deadline to apply for a position at NIH, the NIH researcher made some calls and discovered a spot there had just opened up — one that was perfect for Dr. Lane, who would spend the ensuing decades conducting life-saving research to understand and combat some of the world’s most dangerous infectious diseases.

Now the Clinical Director at the National Institute for Allergy and Infectious Disease (NIAID), Dr. Lane has been named a finalist for the 2022 Samuel J. Heyman Service to America Medals’ Career Achievement Award in recognition of his crucial contributions to the fight against HIV/AIDS, Ebola, COVID-19, and other illnesses. Also known as the “Sammies,” the awards recognize federal employees who are “breaking down barriers, overcoming huge challenges, and getting results.”

IRP’s Heinz Feldmann Elected to National Academy of Medicine

Vaccine Research Facilitated Rapid Response to Ebola Outbreak

Dr. Heinz Feldmann

IRP Senior Investigator Heinz Feldmann, M.D., was elected to the National Academy of Medicine (NAM) last year for leading the development of the technology that resulted in the first Ebola vaccine approved by the US Food and Drug Administration (FDA) and used by the World Health Organization (WHO) to combat the deadly disease. Election to the NAM is considered one of the highest honors in the fields of health and medicine.

As chief of the Laboratory of Virology at the National Institute of Allergy and Infectious Diseases (NIAID), Dr. Feldmann’s work focuses on viruses like Ebola that cause hemorrhagic fever, a condition marked by fever, weakness, muscle pain, and sometimes bleeding. These highly contagious viruses require specialized laboratories and strict safety procedures to study.

An Ebola Therapy Two Decades in the Making

IRP Researcher Nancy Sullivan Led Development of Cutting-Edge Treatment

a volunteer receives an infusion of an experimental Ebola therapy during a phase I clinical trial

Twenty-four years before the novel coronavirus began spreading in Wuhan, China, an outbreak of another deadly virus burned through the city of Kikwit in what is now the Democratic Republic of Congo. Between January and August of 1995, 316 people are thought to have contracted Ebola, and 252 of them died. More than a decade later, a team of NIH infectious disease scientists would track down one of the survivors and use a sample of the individual’s blood to produce one of the first effective treatments for Ebola.

NIH Research Festival Hosts Postdoc Poster-Palooza

Annual Event Highlights Contributions of IRP Postdoctoral Fellows

Dr. Subhash Verma

At lunchtime last Wednesday, the NIH Clinical Center’s FAES Terrace echoed with the joyful sounds of scientists nourishing their bodies and their brains. While those stopping by the annual NIH Research Festival poster session could be forgiven for making a beeline straight for the food — including the submissions to this year’s Scientific Directors’ baking competition — once their plates were full, they took advantage of the opportunity to satiate their scientific curiosity as well by checking out the dozens of posters on display.

New in NIH History

We haven’t shared recent additions to the NIH Stetten Museum collection in a long time, so you’re in for a treat this month!

balance and Gene Hughes

Ebola Virus: Lessons from a Unique Survivor

Reblogged from The NIH Director's Blog.

Ebola virus (green) is shown on cell surface

There are new reports of an outbreak of Ebola virus disease in the Democratic Republic of Congo. This news comes just two years after international control efforts eventually contained an Ebola outbreak in West Africa, though before control was achieved, more than 11,000 people died—the largest known Ebola outbreak in human history. Many questions remain about why some people die from Ebola and others survive. Now, some answers are beginning to emerge thanks to a new detailed analysis of the immune responses of a unique Ebola survivor, a 34-year-old American health-care worker who was critically ill and cared for at the NIH Special Clinical Studies Unit in 2015.

NIH Nurses Play Critical Roles in Cancer and Ebola Discovery

In 2007, the NIH Clinical Center (CC) established two research nursing roles that are critical to the success of the many studies undertaken at the CC. Clinical Research Nurses (CRN) are staff nurses who focus on caring for research participants, while also providing support for studies in a clinical delivery setting. Research Nurse Coordinators (RCN) are responsible for managing research studies and enormous amounts of data collection. They are in charge of recruiting and enrolling participants, maintaining study consistency, and overseeing regulatory adherence.

NIH Special Clinical Studies Unit Nurse

President Obama Visits Ebola Vaccine Lab as Women Make History

The Ebola vaccine developed by Dr. Nancy Sullivan at NIAID is a Women’s History Month highlight: women developed the vaccine and coordinated and led the clinical trial, and a woman was the first volunteer to receive the vaccine. “That wasn’t planned, but it’s kind of remarkable,” said Sullivan. She explained her work to President Barack Obama in person.

Sullivan with Obama

Ebola: Scientific Research in Search of a Public Health Solution

As the international community continues to seek collaborative approaches to contain and eradicate the current Ebola outbreak in West Africa, we are reminded that these efforts are also an investment in our own public health. Only by defeating a virus at its source can we prevent infectious diseases from spreading to other countries.

Ebola